Breadcrumb

Sofia R. Gameiro, Ph.D.

Sofia R. Gameiro, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology

RESEARCH SUMMARY

Dr. Gameiro is a Staff Scientist and Head of the Molecular Immunology Group of the Center for Immuno-Oncology, NCI. This group examines how emerging therapeutics can modulate the immune system to exert potent antitumor activity, with particular emphasis on how the mechanisms involved can be exploited to maximize antitumor activity in combination regimens with novel immunotherapies and other anticancer modalities.

Dr. Gameiro received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo, NY. Dr. Gameiro's research interests include immune modulation; tumor microenvironment; tumor immunology. The Molecular Immunology Group examines how emerging therapeutics can modulate the immune system to exert potent antitumor activity, with particular emphasis on how the mechanisms involved can be exploited to maximize antitumor activity in combination regimens with novel immunotherapies and other anticancer modalities. These studies form the rationale for novel hypothesis-driven clinical interventions.
 

Areas of Expertise

1) cancer immunotherapy, 2) immune modulation

Publications

Selected Key Publications

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

Minnar CM, Chariou PL, Horn LA, Hicks KC, Palena C, Schlom J, Gameiro SR
J ImmunoTher Cancer. 10(6): e004561, 2022.
Full-Text Article
[ Journal Article ]

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Hicks KC, Chariou PL, Ozawa Y, Minnar CM, Knudson KM, Meyer TJ, Bian J, Cam M, Schlom J, Gameiro SR.
Nat Commun.. 12(1): 5151, 2021.
Full-Text Article
[ Journal Article ]

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa

Ozawa Y, Hicks KC, Minnar CM, Knudson KM, Schlom J, Gameiro SR
Oncoimmunology. 10(1): 1915561, 2021.
Full-Text Article
[ Journal Article ]

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR
J Immunother Cancer. 8: e000493, 2020. [ Journal Article ]

Cooperative immune-mediated mechanisms of the HDAC inhibitor entinostat, an IL-15 superagonist, and a cancer vaccine effectively synergize as a novel cancer therapy

Hicks KC, Knudson KM, Lee KL, Hamilton DH, Hodge JW, Figg WD, Ordentlich P, Jones R, Rabizadeh H, Soon-Shiong P, Schlom J, Gameiro SR
Clin Cancer Res. 26: 704-16, 2020. [ Journal Article ]

Team

Sarah Khelifa
Postdoctoral Fellow (CRTA)
Sarah Khelifa, PhD
Katherine E. Lothstein
Postdoctoral Fellow (CRTA)
Katherine E. Lothstein, PhD
Grace Lui
Post-baccalaureate (pre-CRTA)
Grace Lui
Christine M. Minnar
Postdoctoral Fellow (CRTA)
Christine M. Minnar, Ph.D.
Curtis Randolph
Biological Science Laboratory Technician (Animal)
Curtis Randolph